380 related articles for article (PubMed ID: 25460020)
21. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
22. Walking on thin ice: the use of triple antidepressant combinations in refractory melancholic depression.
Restifo S
Australas Psychiatry; 2012 Apr; 20(2):134-7. PubMed ID: 22467559
[TBL] [Abstract][Full Text] [Related]
23. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study.
Köhler S; Unger T; Hoffmann S; Steinacher B; Fydrich T; Bschor T
Pharmacopsychiatry; 2013 Mar; 46(2):69-76. PubMed ID: 23093475
[TBL] [Abstract][Full Text] [Related]
24. Medication options in the treatment of treatment-resistant depression.
Pridmore S; Turnier-Shea Y
Aust N Z J Psychiatry; 2004 Apr; 38(4):219-25. PubMed ID: 15038800
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms underlying the antidepressant response and treatment resistance.
Levinstein MR; Samuels BA
Front Behav Neurosci; 2014; 8():208. PubMed ID: 25018708
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
Nguyen KH; Gordon LG
Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
[TBL] [Abstract][Full Text] [Related]
27. Assessing the risk factors for difficult-to-treat depression and treatment-resistant depression.
Gaynes B
J Clin Psychiatry; 2016 Feb; 77 Suppl 1():4-8. PubMed ID: 26829431
[TBL] [Abstract][Full Text] [Related]
28. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
[TBL] [Abstract][Full Text] [Related]
29. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.
Papakostas GI; Ionescu DF
Mol Psychiatry; 2015 Oct; 20(10):1142-50. PubMed ID: 26148812
[TBL] [Abstract][Full Text] [Related]
30. Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models.
Zabegalov KN; Kolesnikova TO; Khatsko SL; Volgin AD; Yakovlev OA; Amstislavskaya TG; Alekseeva PA; Meshalkina DA; Friend AJ; Bao W; Demin KA; Gainetdinov RR; Kalueff AV
Eur J Pharmacol; 2018 Jun; 829():129-140. PubMed ID: 29627310
[TBL] [Abstract][Full Text] [Related]
31. The role of CREB in depression and antidepressant treatment.
Blendy JA
Biol Psychiatry; 2006 Jun; 59(12):1144-50. PubMed ID: 16457782
[TBL] [Abstract][Full Text] [Related]
32. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.
Lauterbach EC
Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777
[TBL] [Abstract][Full Text] [Related]
33. Frontiers in Therapy of Treatment-Resistant-Depression: A Future Role of Ketamine?
Kwak S; Tiller D; Tucker P
J Okla State Med Assoc; 2015 Mar; 108(3):88-9. PubMed ID: 26242015
[TBL] [Abstract][Full Text] [Related]
34. Animal models of major depression: drawbacks and challenges.
Planchez B; Surget A; Belzung C
J Neural Transm (Vienna); 2019 Nov; 126(11):1383-1408. PubMed ID: 31584111
[TBL] [Abstract][Full Text] [Related]
35. Adding smartphone-based cognitive-behavior therapy to pharmacotherapy for major depression (FLATT project): study protocol for a randomized controlled trial.
Watanabe N; Horikoshi M; Yamada M; Shimodera S; Akechi T; Miki K; Inagaki M; Yonemoto N; Imai H; Tajika A; Ogawa Y; Takeshima N; Hayasaka Y; Furukawa TA;
Trials; 2015 Jul; 16():293. PubMed ID: 26149441
[TBL] [Abstract][Full Text] [Related]
36. The Role of Nitric Oxide in the Antidepressant Actions of 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside in Insulin-Resistant Mice.
Liu W; Wang Y; Li H; Ji L
Psychosom Med; 2016 Jan; 78(1):102-12. PubMed ID: 26569535
[TBL] [Abstract][Full Text] [Related]
37. Rodent models in depression research: classical strategies and new directions.
Pollak DD; Rey CE; Monje FJ
Ann Med; 2010 May; 42(4):252-64. PubMed ID: 20367120
[TBL] [Abstract][Full Text] [Related]
38. Glucagon-like peptide-2 but not imipramine exhibits antidepressant-like effects in ACTH-treated mice.
Iwai T; Ohnuki T; Sasaki-Hamada S; Saitoh A; Sugiyama A; Oka J
Behav Brain Res; 2013 Apr; 243():153-7. PubMed ID: 23333402
[TBL] [Abstract][Full Text] [Related]
39. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?
Fornaro M; Aguglia E; Dell'Osso L; Perugi G
Expert Opin Pharmacother; 2011 Dec; 12(18):2817-31. PubMed ID: 22098226
[TBL] [Abstract][Full Text] [Related]
40. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice.
Cryan JF; Mombereau C; Vassout A
Neurosci Biobehav Rev; 2005; 29(4-5):571-625. PubMed ID: 15890404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
